Abl Bio Inc.

Yuhan Corporation

Legochem Biosciences, Inc.

Donghoon Yeom

Yangsoon Lee

Kyungjin Park

Juhee Kim

Yeunju Kim

Byungje Sung

Hyejin Chung

Jinhyung Ahn

Kyeongsu Park

Jiseon Yoo

Daehae Song

Eunsil Sung

Eunyoung Park

Eun-Jung Lee

Youngdon Pak

Yong-Gyu Son

Jaehyun Eom

Seawon Ahn

Eunjung Kim

Ui-Jung Jung

Jinwon Jung

Dongin Kim

Sang Hoon Lee

Yong Zu Kim

Ho Young Song

Ju Young Lee

Jeiwook Chae

Sung Min Kim

Moo Young Song

Hyoung Rae Kim

Kyung Eun Park

Chang Sun Lee

Dae Hyuck Kang

Ji Hye Oh

Jaeho Jung

Na Rae Lee

Yun-Hee Park

Minji Park

Young Bong Park

Hyeun Joung Lee

Sungwon An

Wonjun Son

Hyun Min Ryu

JinWon Jung

Taewang Kim

Yeryoung Yong

Yoseob Lee

Chanmoo Lee

Junghyeon Hong

Junhyun Jeong

Jaehyoung Jeon

Mikyung Chang

Weonkyoo You

Youngeun Hong

Ji-Na You

Nara Han

Young-Jae Yang

Ju Yuel Baek

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Anti-BCMA antibody and use thereof

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

Growing community of inventors

Seongnam-si, South Korea

Donghoon Yeom